Literature DB >> 31150976

Per- and polyfluoroalkyl substances and blood lipid levels in pre-diabetic adults-longitudinal analysis of the diabetes prevention program outcomes study.

Pi-I D Lin1, Andres Cardenas2, Russ Hauser3, Diane R Gold4, Ken P Kleinman5, Marie-France Hivert6, Abby F Fleisch7, Antonia M Calafat8, Thomas F Webster9, Edward S Horton10, Emily Oken11.   

Abstract

Exposure to per- and polyfluoroalkyl substances (PFASs) may interfere with lipid regulation. However, most previous studies were cross-sectional with the risk of reverse causation, suggesting a need for long-term prospective studies. We examined the relationship of baseline plasma PFAS concentrations with repeated measures of blood lipids. We included 888 prediabetic adults from the Diabetes Prevention Program (DPP) and DPP Outcomes Study, who had measurements of 6 plasma PFAS concentrations at baseline (1996-1999) and repeated measures of blood lipids over 15 years of follow-up, and were initially randomized to placebo or a lifestyle intervention. We used linear regression to examine cross-sectional associations of PFAS concentrations and lipid levels at baseline, and evaluated prospective risks of hypercholesterolemia and hypertriglyceridemia using Cox proportional hazard models, and tested for effect modification by study arm. Participants (65.9% female, 57.0% White, 65.9% aged 40-59 years) had comparable PFAS concentrations [e.g., median (IQR) perfluorooctanoic acid (PFOA) 4.9 ng/mL (3.2)] with the general U.S. population in 1999-2000. We observed higher total cholesterol at baseline per doubling of PFOA (β: 6.1 mg/dL, 95% CI: 3.1, 9.04), perfluorohexane sulfonic acid (PFHxS, β: 2.2 mg/dL, 95% CI: 0.2, 4.3), and perfluorononanoic acid (PFNA, β: 2.9 mg/dL, 95% CI: 0.7, 5.0). Prospectively, baseline concentrations of several PFASs, including PFOA, PFOS, PFHxS and PFNA, predicted higher risks of incident hypercholesterolemia and hypertriglyceridemia, but only in the placebo group and not the lifestyle intervention group. For example, participants in the placebo group with PFOA concentration > median (4.9 ng/mL) were almost twice as likely (HR: 1.90, 95% CI: 1.25, 2.88) to develop hypertriglyceridemia compared to those ≤median. Findings suggest adverse effects of some PFASs on lipid profiles in prediabetic adults. However, the detrimental effect was attenuated with a lifestyle intervention.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Environmental epidemiology; Hyperlipidemia; Lifestyle intervention; Lipid and cholesterol; Per- and polyfluoroalkyl substances; Prospective assessment

Mesh:

Substances:

Year:  2019        PMID: 31150976      PMCID: PMC6570418          DOI: 10.1016/j.envint.2019.05.027

Source DB:  PubMed          Journal:  Environ Int        ISSN: 0160-4120            Impact factor:   9.621


  63 in total

1.  Association of polyfluoroalkyl chemical exposure with serum lipids in children.

Authors:  Xiao-Wen Zeng; Zhengmin Qian; Brett Emo; Michael Vaughn; Jia Bao; Xiao-Di Qin; Yu Zhu; Jie Li; Yungling Leo Lee; Guang-Hui Dong
Journal:  Sci Total Environ       Date:  2015-01-30       Impact factor: 7.963

2.  Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study.

Authors:  T J Orchard; M Temprosa; E Barrett-Connor; S E Fowler; R B Goldberg; K J Mather; S M Marcovina; M Montez; R E Ratner; C D Saudek; H Sherif; K E Watson
Journal:  Diabet Med       Date:  2013-01       Impact factor: 4.359

3.  Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project.

Authors:  Stephanie J Frisbee; Anoop Shankar; Sarah S Knox; Kyle Steenland; David A Savitz; Tony Fletcher; Alan M Ducatman
Journal:  Arch Pediatr Adolesc Med       Date:  2010-09

4.  Associations between PFOA, PFOS and changes in the expression of genes involved in cholesterol metabolism in humans.

Authors:  Tony Fletcher; Tamara S Galloway; David Melzer; Paul Holcroft; Riccardo Cipelli; Luke C Pilling; Debapriya Mondal; Michael Luster; Lorna W Harries
Journal:  Environ Int       Date:  2013-04-24       Impact factor: 9.621

5.  Improved selectivity for the analysis of maternal serum and cord serum for polyfluoroalkyl chemicals.

Authors:  Kayoko Kato; Brian J Basden; Larry L Needham; Antonia M Calafat
Journal:  J Chromatogr A       Date:  2010-10-21       Impact factor: 4.759

6.  Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population.

Authors:  Jessica W Nelson; Elizabeth E Hatch; Thomas F Webster
Journal:  Environ Health Perspect       Date:  2010-02       Impact factor: 9.031

7.  The association between PFOA, PFOS and serum lipid levels in adolescents.

Authors:  Sarah Dee Geiger; Jie Xiao; Alan Ducatman; Stephanie Frisbee; Kim Innes; Anoop Shankar
Journal:  Chemosphere       Date:  2013-11-13       Impact factor: 7.086

8.  Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.

Authors:  Xiaoqiang Xiang; Yi Han; Mikko Neuvonen; Marja K Pasanen; Annikka Kalliokoski; Janne T Backman; Jouko Laitila; Pertti J Neuvonen; Mikko Niemi
Journal:  Pharmacogenet Genomics       Date:  2009-06       Impact factor: 2.089

9.  Early life exposure to per- and polyfluoroalkyl substances and mid-childhood lipid and alanine aminotransferase levels.

Authors:  Ana M Mora; Abby F Fleisch; Sheryl L Rifas-Shiman; Jennifer A Woo Baidal; Larissa Pardo; Thomas F Webster; Antonia M Calafat; Xiaoyun Ye; Emily Oken; Sharon K Sagiv
Journal:  Environ Int       Date:  2017-11-20       Impact factor: 9.621

10.  Gastrointestinal Elimination of Perfluorinated Compounds Using Cholestyramine and Chlorella pyrenoidosa.

Authors:  Stephen J Genuis; Luke Curtis; Detlef Birkholz
Journal:  ISRN Toxicol       Date:  2013-09-09
View more
  22 in total

1.  The role of maternal high fat diet on mouse pup metabolic endpoints following perinatal PFAS and PFAS mixture exposure.

Authors:  Emily S Marques; Juliana Agudelo; Emily M Kaye; Seyed Mohamad Sadegh Modaresi; Marisa Pfohl; Jitka Bečanová; Wei Wei; Marianne Polunas; Michael Goedken; Angela L Slitt
Journal:  Toxicology       Date:  2021-08-28       Impact factor: 4.571

2.  Per- and Polyfluoroalkyl Substances and Incident Hypertension in Multi-Racial/Ethnic Women: The Study of Women's Health Across the Nation.

Authors:  Ning Ding; Carrie A Karvonen-Gutierrez; Bhramar Mukherjee; Antonia M Calafat; Siobán D Harlow; Sung Kyun Park
Journal:  Hypertension       Date:  2022-06-13       Impact factor: 9.897

3.  Multi- and Transgenerational Effects of Developmental Exposure to Environmental Levels of PFAS and PFAS Mixture in Zebrafish (Danio rerio).

Authors:  Alex Haimbaugh; Chia-Chen Wu; Camille Akemann; Danielle N Meyer; Mackenzie Connell; Mohammad Abdi; Aicha Khalaf; Destiny Johnson; Tracie R Baker
Journal:  Toxics       Date:  2022-06-18

4.  Per- and polyfluoroalkyl substances and blood pressure in pre-diabetic adults-cross-sectional and longitudinal analyses of the diabetes prevention program outcomes study.

Authors:  Pi-I D Lin; Andres Cardenas; Russ Hauser; Diane R Gold; Ken P Kleinman; Marie-France Hivert; Antonia M Calafat; Thomas F Webster; Edward S Horton; Emily Oken
Journal:  Environ Int       Date:  2020-02-20       Impact factor: 9.621

5.  Per- and polyfluoroalkyl substance plasma concentrations and metabolomic markers of type 2 diabetes in the Diabetes Prevention Program trial.

Authors:  Susanna D Mitro; Jinxi Liu; Lindsay M Jaacks; Abby F Fleisch; Paige L Williams; William C Knowler; Blandine Laferrère; Wei Perng; George A Bray; Amisha Wallia; Marie-France Hivert; Emily Oken; Tamarra M James-Todd; Marinella Temprosa
Journal:  Int J Hyg Environ Health       Date:  2020-12-18       Impact factor: 5.840

6.  Per- and polyfluoroalkyl substances and kidney function: Follow-up results from the Diabetes Prevention Program trial.

Authors:  Pi-I D Lin; Andres Cardenas; Russ Hauser; Diane R Gold; Ken P Kleinman; Marie-France Hivert; Antonia M Calafat; Thomas F Webster; Edward S Horton; Emily Oken
Journal:  Environ Int       Date:  2021-01-19       Impact factor: 9.621

7.  Perfluoroalkyl substances and cognitive function in older adults: Should we consider non-monotonic dose-responses and chronic kidney disease?

Authors:  Sung Kyun Park; Ning Ding; Dehua Han
Journal:  Environ Res       Date:  2020-10-15       Impact factor: 6.498

Review 8.  Exposure to Perfluoroalkyl Chemicals and Cardiovascular Disease: Experimental and Epidemiological Evidence.

Authors:  Alessandra Meneguzzi; Cristiano Fava; Marco Castelli; Pietro Minuz
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-09       Impact factor: 5.555

9.  Impact of "healthier" materials interventions on dust concentrations of per- and polyfluoroalkyl substances, polybrominated diphenyl ethers, and organophosphate esters.

Authors:  Anna S Young; Russ Hauser; Tamarra M James-Todd; Brent A Coull; Hongkai Zhu; Kurunthachalam Kannan; Aaron J Specht; Maya S Bliss; Joseph G Allen
Journal:  Environ Int       Date:  2020-10-19       Impact factor: 9.621

10.  Associations of perfluoroalkyl and polyfluoroalkyl substances (PFAS) and PFAS mixtures with adipokines in midlife women.

Authors:  Ning Ding; Carrie A Karvonen-Gutierrez; William H Herman; Antonia M Calafat; Bhramar Mukherjee; Sung Kyun Park
Journal:  Int J Hyg Environ Health       Date:  2021-06-02       Impact factor: 7.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.